Investigate / reported ownership
BAX
Baxter International Inc
9 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.
Who reports owning BAX?
Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Richard Pzena | 4.1% | 14q | $1.39B | 65,295,393 |
| 2 | Dodge & Cox Funds | 0.7% | 33q | $1.24B | 58,386,345 |
| 3 | Greenhaven Associates | 3.5% | 4q | $305M | 14,285,228 |
| 4 | First Pacific Advisors | 2.0% | 2q | $162M | 7,618,145 |
| 5 | Robert Olstein | 1.7% | 36q | $8M | 464,000 |
Go beyond ownership.
Baxter sells essential hospital and care-setting products, including IV solutions, infusion systems, parenteral nutrition, generic injectables, smart beds and patient monitoring, to hospitals, nursing homes, surgery centers, clinics and home patients.
Question to investigate: Can Baxter's smaller, reorganized portfolio sustain its operations while resolving the Novum LVP shipment hold and working through restructuring?
Company research reviewed 2026-10-02; a dated source-linked starting point, not the investors’ stated reasons.
Understand the business and investment case →Filing dates and original SEC sources
- Richard Pzena · 2026Q2 · filed 2026-08-07 ↗
- Dodge & Cox Funds · 2026Q2 · filed 2026-08-13 ↗
- Greenhaven Associates · 2026Q2 · filed 2026-07-28 ↗
- First Pacific Advisors · 2026Q2 · filed 2026-08-14 ↗
- Robert Olstein · 2026Q1 · filed 2026-04-21 ↗
- Hillman Capital Management · 2026Q2 · filed 2026-08-14 ↗
- Joel Greenblatt · 2026Q2 · filed 2026-09-02 ↗
- Mairs & Power Funds · 2026Q2 · filed 2026-08-14 ↗
- Tweedy Browne · 2026Q2 · filed 2026-08-07 ↗
Keep your next step small.
Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.
Record my own view →Optional email follow
Latticework Follow
Follow BAX
Email me only when a reviewed weekly edition contains a material new decision about BAX: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.
Confirm by email. Manage or stop follows in one click. See our privacy notice.
Long US 13F disclosures omit shorts and can be amended. CUSIP 071813109. No current price, valuation or manager motive is inferred.